Travere Therapeutics appoints Christopher Cline as CFO with $430k salary, equity grants

Travere Therapeutics, Inc.

Christopher Cline named CFO effective September 1, 2022, replacing retiring Laura Clague.
Annual base salary of $430,000; target annual bonus of 50% of base salary.
Equity grants: stock option for 48,000 shares, Time-Based RSU for 5,000 shares, PSUs for 9,840 shares.
Laura Clague steps down as CFO on August 31, 2022, remains through Q1 2023 for transition.
Severance provisions include 12-month cash continuation and accelerated vesting under certain conditions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laura Clague

Chief Financial Officer

TVTX · Travere Therapeutics, Inc.

Effective: 2022-08-31
Successor: Christopher Cline
Filed: August 17, 2022, 7:59 PM ET

On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022

Appointed

Christopher Cline

Chief Financial Officer

TVTX · Travere Therapeutics, Inc.

Effective: 2022-09-01
Filed: August 17, 2022, 7:59 PM ET

Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of September 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Clague departed as Chief Financial Officer at Travere Therapeutics, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Cline was appointed as Chief Financial Officer at Travere Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of September 1, 2022.

View on SEC.gov

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-22-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.